SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Acumen Pharmaceuticals, Inc. (ABOS) News

Follow Acumen Pharmaceuticals, Inc. (ABOS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ABOS Asset equity Sector Markets 90 days 18 Last 0.1946 Updated Nov 05, 2026, 09:05 PM UTC Open live news feed Open ABOS chart & news
L Acumen Repays K2 HealthVentures Loan for Approximately $23.3 Million Acumen repaid approximately $23.3 million to K2 HealthVentures on November 5, 2026, terminating its November 2023 loan agreement ahead of its scheduled November 2027 maturity. The payoff included outstanding principal, a EQUITY | Nov 05, 2026, 09:05 PM UTC H Acumen Pharmaceuticals shares fall 75% premarket Acumen Pharmaceuticals (ABOS) shares fell 75% before the market open. EQUITY | Oct 30, 2026, 11:31 AM UTC M Dicot Pharma’s Q3 loss widens Sweden-based Dicot Pharma reported a wider loss in Q3. EQUITY | Oct 28, 2026, 07:15 AM UTC M ABOS Reports Fiscal Q3 Net Loss The company reported a fiscal 2026 third-quarter loss attributable to shareholders, up 18.06% year over year, and negative basic earnings per share. EQUITY | Oct 27, 2026, 04:29 AM UTC M Acumen Pharmaceuticals Reports Third-Quarter 2026 Net Loss of $25.4 Million Acumen reported a diluted loss per share of $0.35, narrowed from $0.44 a year earlier. Its net loss was $25.4 million, compared with $26.5 million in the year-ago quarter. EQUITY | Oct 26, 2026, 08:11 PM UTC M Acumen Pharmaceuticals Reports Quarterly Results for Quarter Ended September 30 EQUITY | Oct 26, 2026, 01:31 PM UTC M Acumen Pharmaceuticals Q3 Net Loss Narrows to $25.37 Million Acumen Pharmaceuticals reported a Q3 2026 net loss of $25.37 million, narrower year over year. EQUITY | Oct 26, 2026, 11:11 AM UTC M Acumen Pharmaceuticals Reports Q3 Income From Operations Acumen Pharmaceuticals reported Q3 income from operations, compared with an IBES estimate of USD -30.7 million. EARNINGS | Oct 26, 2026, 11:06 AM UTC M Acumen Pharmaceuticals Reports Third-Quarter 2026 Financial Results The company expects to report topline results from its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193). EQUITY | Oct 26, 2026, 11:03 AM UTC M Acumen Pharmaceuticals to Report Third-Quarter Results October 26 Acumen Pharmaceuticals said it will report third-quarter financial results on October 26, 2026. EQUITY | Oct 19, 2026, 08:00 PM UTC L Acumen Pharmaceuticals Is Maintained at Buy by Citigroup Ratings actions from Benzinga: GMT) Acumen Pharmaceuticals Price Target Raised to $5.00/Share From $4.00 by CitigroupRatings actions from Benzinga NEWS | Sep 15, 2026, 04:30 PM UTC L Acumen Pharmaceuticals to hold virtual investor day on September 16, 2026 Acumen Pharmaceuticals said it will hold a virtual investor day on September 16, 2026. The announcement comes from the company and refers to its clinical-stage biopharmaceutical work in Alzheimer’s disease. EQUITY | Sep 10, 2026, 08:01 PM UTC L Acumen Pharmaceuticals to hold virtual investor day Sept. 16, 2026 EQUITY | Sep 10, 2026, 08:00 PM UTC L ABOS: Phase IIb Alzheimer's data and advanced brain delivery program set stage for future breakthroughs The conference highlighted a robust Alzheimer's pipeline, with phase IIb data for sabirnetug expected late this year and a novel EBD program targeting enhanced brain delivery. Strong trial execution, positive KOL feedbac EQUITY | Sep 10, 2026, 02:14 PM UTC L ABOS: Phase II trial of sabirnetug targets toxic oligomers in Alzheimer's, with pivotal data due late 2026 The conference highlighted a rapidly growing Alzheimer's market and detailed the phase II ALTITUDE-AD trial of sabirnetug, targeting toxic A-beta oligomers with data expected in late 2026. Strong KOL support, robust tria EQUITY | Sep 10, 2026, 01:42 PM UTC L ABOS: Phase II data for a novel Alzheimer's antibody is expected in Q4 2024, with EBD IND in 2027 Sabirnetug, a selective A-beta oligomer antibody, is in phase II for early Alzheimer's, with data expected in late 2024. The Enhanced Brain Delivery program, leveraging JCR's technology, targets an IND in mid-2027. Key m EQUITY | Sep 09, 2026, 10:09 PM UTC L ABOS: Phase II data for a novel Alzheimer's antibody and brain delivery tech are expected by Q4 and 2027 The discussion highlighted progress on sabirnetug, a selective Aβ oligomer antibody for early Alzheimer's, with phase II data expected in Q4. The Enhanced Brain Delivery program, leveraging JCR's technology, aims for an EQUITY | Sep 09, 2026, 09:18 PM UTC L ABOS - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences ABOS - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences EQUITY | Sep 02, 2026, 08:00 PM UTC L ABOS Reports Q2 2026 Financial Results ABOS reports second quarter 2026 financial results and business highlights EARNINGS | Aug 12, 2026, 11:00 AM UTC L ABOS - Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 ABOS - Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 EARNINGS | Aug 05, 2026, 08:00 PM UTC L ABOS Acumen Pharmaceuticals - ebd bispecific antibodies show improved brain penetration compared to native anti-aβo antibodies - No hematolo ABOS Acumen Pharmaceuticals - ebd bispecific antibodies show improved brain penetration compared to native anti-aβo antibodies - No hematological safety signals observed for acu401 in non-human primates EQUITY | Jul 15, 2026, 11:30 AM UTC